GlassScriptPhysician profile
Bora V Kim
NPI 1336305390
$9,446.33
in general payments reported to CMS, 2019-2025
23 companies · $2,703 in 2025
The $2,703 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $566 · 2020: $161 · 2021: $617 · 2022: $1,262 · 2023: $1,797 · 2024: $2,340 · 2025: $2,703.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,522 · Education: $318.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,522.28 |
| Education | $317.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $3,000.43 | 2021-2025 | Micra, Cobalt Dr Mri Surescan, Aurora Ev-Icd Mri Surescan |
| Genzyme Corporation | $1,676.96 | 2021-2025 | |
| Glaxosmithkline, LLC. | $1,228.92 | 2019-2025 | Nucala, Trelegy Ellipta |
| Optinose US, INC. | $825.18 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $561.45 | 2019-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $404.47 | 2019-2025 | Fasenra, Tezspire |
| Sanofi-Aventis U.S. LLC | $317.92 | 2023-2025 | |
| Amgen INC. | $269.96 | 2022-2025 | Tezspire |
| Alk-Abello, INC | $243.33 | 2019-2025 | Grastek, Odactra, Ragwitek |
| Hikma Pharmaceuticals USA | $183.61 | 2022-2024 | Ryaltris |
| Acclarent, INC | $143.77 | 2021-2022 | |
| Kaleo, INC. | $105.24 | 2021-2024 | Auvi-Q |
| Teva Pharmaceuticals USA, INC. | $91.90 | 2019 | |
| Novartis Pharmaceuticals Corporation | $84.32 | 2019-2025 | |
| Aerin Medical INC. | $52.48 | 2024-2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ars Pharmaceuticals Operations, INC. | $49.60 | 2025 | Neffy |
| Genentech USA, INC. | $39.14 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.56 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.10 | 2024 | |
| Grifols USA, LLC | $29.30 | 2025 | Xembify |
| Integra Lifesciences Corporation | $28.15 | 2024 | Acclarent Aera |
| Merck Sharp & Dohme LLC | $23.75 | 2023 | |
| Inspire Medical Systems, INC. | $19.79 | 2025 | Inspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bora Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.